Abstract: The present invention concerns novel antibody variants, particularly anti-HER2 antibody variants having substitutions at positions within the variable domains of the heavy and light chains.
Type:
Grant
Filed:
December 13, 2010
Date of Patent:
September 23, 2014
Assignee:
Genentech, Inc.
Inventors:
Henry B. Lowman, Resi B. Gerstner, Paul J. Carter
Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, A, X1, X2, X3, X4, X5, X6, Y, Z, G, R1a, R2a, R1b, R2b, R3, R4, R5 and R6 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
Type:
Application
Filed:
March 14, 2014
Publication date:
September 18, 2014
Applicant:
Genentech, Inc.
Inventors:
Benjamin Fauber, Olivier Rene, Monique Bodil van Niel, Stuart Ward
Abstract: The invention provides combinations comprising a MEK inhibitor (such as GDC-0973 or GDC-0623), or a pharmaceutically acceptable salt thereof and a HER3/EGFR inhibitor (such as MEHD7945A). The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
Type:
Application
Filed:
March 14, 2014
Publication date:
September 18, 2014
Applicants:
The Regents of the University of California, Genentech, Inc.
Inventors:
Mark X. Sliwkowski, Wolfgang Michael Korn
Abstract: The invention provides a combination of a) a compound of Formula Ia: [insert Formula Ia], or a pharmaceutically acceptable salt thereof, and b) vemurafenib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.
Abstract: Processes are described for the preparation of PI3K inhibitor, GDC-0032, Formula I, having the structure: and intermediates useful for the preparation of I.
Type:
Application
Filed:
March 12, 2014
Publication date:
September 18, 2014
Applicant:
Genentech, Inc.
Inventors:
Remy Angelaud, Danial R. Beaudry, Diane E. Carrera, Sushant Malhotra, Travis Remarchuk, Frederic St-Jean
Abstract: The invention provides novel compounds that are inhibitors of IAPs having the general formula: wherein X1, X2, X3, Y, A, R1, R2, R3, R4, R4?, R5, R5?, R6 and R6? are as described herein. The compouds of the invention may be used to induce apoptosis in cells (or sensitise cells to apoptosis) in which IAPs are overexpressed or otherwise implicated in resistance to normal apoptotic processes. Accordingly, the compounds may be provided in pharmaceutically acceptable compositions and used for the treatment cancers.
Type:
Grant
Filed:
July 23, 2009
Date of Patent:
September 16, 2014
Assignee:
Genentech, Inc.
Inventors:
Danette Dudley, John A. Flygare, Chudi Ndubaku
Abstract: The present invention provides compounds, including pharmaceutically acceptable salts thereof, comprising the Formula (I): Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases, such as cancer.
Type:
Grant
Filed:
January 9, 2009
Date of Patent:
September 16, 2014
Assignees:
Array Biopharma, Inc., Genentech, Inc.
Inventors:
Josef R. Bencsik, James F. Blake, Nicholas C. Kallan, Ian S. Mitchell, Keith Lee Spencer, Dengming Xiao, Rui Xu, Christine Chabot, Steven Do, Jun Liang, Brian Safina, Birong Zhang
Abstract: The invention provides a combination of a) a compound of Formula (Ia): or a pharmaceutically acceptable salt thereof, and b) abiraterone or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.
Abstract: The present invention relates to compounds of Formula I: wherein R1, R2, R3, A1, A2, A3, A4, Y1 and Y2 and D have the meaning described herein. The present invention also relates to pharmaceutical compositions comprising such compounds and therapeutic uses thereof.
Type:
Grant
Filed:
November 10, 2010
Date of Patent:
September 9, 2014
Assignee:
Genentech, Inc.
Inventors:
Zhonghua Pei, Joseph P. Lyssikatos, Wendy Lee, Kirk D. Robarge
Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
Type:
Application
Filed:
September 6, 2013
Publication date:
September 4, 2014
Applicant:
Genentech, Inc.
Inventors:
Deepak Sampath, Christian Klein, Wayne John Fairbrother
Abstract: The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.
Type:
Application
Filed:
May 12, 2014
Publication date:
September 4, 2014
Applicant:
Genentech, Inc.
Inventors:
Min Xu, Mercedesz Balazs, Ning Chai, Nancy Chiang, Henry Chiu, Zhonghua Lin, Patrick Lupardus, Gerald R. Nakamura, Hyunjoo Park, Lee Swem
Abstract: The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing EGFR, as determined by a gene amplification assay, with an EGFR antagonist. Such method comprises administering a cancer-treating dose of the EGFR antagonist, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells erbB1 gene has been found to be amplified e.g., by fluorescent in situ hybridization. EGFR antagonists described include an anti-EGFR antibody.
Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
Type:
Application
Filed:
February 14, 2014
Publication date:
September 4, 2014
Applicants:
Genentech, Inc., Array BioPharma Inc.
Inventors:
James F. Blake, Mark Joseph Chicarelli, Rustam Ferdinand Garrey, John Gaudino, Jonas Grina, David A. Moreno, Peter J. Mohr, Li Ren, Jacob Schwarz, Huifen Chen, Kirk Robarge, Aihe Zhou
Abstract: The invention relates to a compound of formula (I) wherein A1, A2 and R1 to R8 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
Type:
Grant
Filed:
February 6, 2013
Date of Patent:
September 2, 2014
Assignee:
Genentech, Inc.
Inventors:
Lilli Anselm, David Banner, Wolfgang Haap, Bernd Kuhn, Thomas Luebbers, Jens-Uwe Peters, Beat Spinnler
Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
Type:
Grant
Filed:
November 9, 2011
Date of Patent:
August 26, 2014
Assignee:
Genentech, Inc.
Inventors:
Charles Baker-Glenn, Daniel Jon Burdick, Mark Chambers, Bryan K. Chan, Huifen Chen, Anthony Estrada, Zachary Kevin Sweeney
Abstract: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist of formula (I) in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.
Type:
Grant
Filed:
March 16, 2012
Date of Patent:
August 26, 2014
Assignees:
Curis, Inc., Genentech, Inc.
Inventors:
Oivin M. Guicherit, Edward Andrew Boyd, Shirley Ann Brunton, Stephen Price, John Harry Alexander Stibbard, Colin H. Mackinnon
Abstract: Compounds having the formula I wherein A, R1a, R1b, R2, R3, R4, R5, R6, R7, R8, Ra, Rb, X1, X2, X3 and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.
Type:
Grant
Filed:
December 21, 2012
Date of Patent:
August 26, 2014
Assignee:
Genentech, Inc.
Inventors:
Ignacio Aliagas-Martin, James Crawford, Wendy Lee, Simon Mathieu, Joachim Rudolph